Introduction
Mycobacterium tuberculosis (MTB) remains a significant disease with 10.4 million new cases of tuberculosis (TB) reported in 2015.
1 Anti-TB therapy is effective in at least 85% of cases when the causative strain of MTB is sensitive to the four drugs (rifampicin [RIF] , isoniazid [INH] , ethambutol, and pyrazinamide) that constitute frontline therapy. 1 Treatment with front-line therapy is less effective when MTB is resistant to one or more of these drugs. 1 It is therefore important to detect MTB resistance to one or more of these front-line drugs so that therapy can be modified appropriately. 1 Detection of drug-resistant MTB is often performed using the accurate but slow (up to 12 weeks) culture-based (phenotypic) drug sensitivity testing (DST). 1 In response to the relative length of time to generate a phenotypic DST result, more rapid nucleic acid amplification tests (NAAT) have been developed. 2 The Cepheid GeneXpert MTB/RIF (Xpert) assay detects mutations associated with RIF resistance while Hain MTBDR Plus (Hain) detects mutations associated with RIF and INH resistance. [3] [4] [5] [6] Abbott RealTime MTB RIF/INH Resistance (RT MTB RIF/INH) detects mutations associated with resistance to RIF and INH. 7 RT MTB RIF/INH is a companion assay to Abbott RealTime MTB (RT MTB). 8, 9 It can be used in direct testing mode to test 
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Kostera et al respiratory specimens (sputum, bronchial alveolar lavage, or N-Acetyl-L-Cysteine (NALC)/NaOH sediments prepared from sputum or bronchial alveolar lavage) or used in reflex mode following a positive RT MTB result. 7 The performance of RT MTB RIF/INH has been studied in in Germany, Hong Kong, and South Africa in reflex mode, following an RT MTB positive result. [10] [11] [12] The intent of this study was to review the performance of RT MTB RIF/INH when used in direct testing mode with MTB culture-positive samples from Bangladesh for which phenotypic DST, Xpert, and Hain results had been generated. The inclusion of DST, as well as Xpert and MTBDR plus results for this patient population provides a measure of performance for RT MTB RIF/INH against phenotypic DST and Xpert and Hain assays.
Methods Samples
Three sputum specimens were collected from 132 subjects suspected of having active TB. Specimens were collected under the supervision of the National TB Reference Lab Institutional Review Board and Intercenter Agreement. All subjects enrolled in this study provided written informed consent. The three sputum specimens were collected from each patient over a maximum period of 5 days, with at least 5 hours between collections. Collection was performed at the National Reference Laboratory in Dhaka, Bangladesh. Specimens were collected following Institutional Review Board approval. The HIV status of each subject was not determined.
Testing
At the National Reference Laboratory, the first sputum sample from each patient was subjected to NALC/NaOH decontamination. The resulting NALC/NaOH pellet was tested using three methods: 1) fluorescent microscopy using the World Health Organization (WHO) scoring system, 2) mycobacterial growth indicator tubes liquid culture with a maximum incubation time of 6 weeks and LowensteinJensen (L-J) solid culture for a maximum incubation time of 8 weeks, and 3) Hain. If culture was positive for MTB, DST was performed using the L-J proportion method using an RIF concentration of 40.0 mcg/mL and an INH concentration of 0.2 mcg/mL. The second sputum from each patient was tested using Xpert. For each subject, if drug resistance results were produced by DST, Hain, and Xpert, the third sputum and residual NALC/NaOH pellet was sent to Abbott Molecular where they were tested using RT MTB RIF/INH.
DNA sequencing
Sanger DNA bidirectional sequencing was performed on samples that had discrepant results between DST and the RT MTB RIF/INH assay.
Data analysis
DST was considered to be the gold standard for determination of RIF and INH drug resistance. The Exact test was used to calculate the 95% CI.
Results
Samples from 132 subjects were included in the study. All 132 subjects had smear, culture, DST, Xpert, and Hain results. RT MTB RIF/INH was used to test all 132 paired NALC/NaOH pellets and sputum samples. The percent of valid RT MTB RIF/INH results was 100% (264/264); no assay inhibition was observed. The percentage of RT MTB RIF/INH results that were above the assay limit of detection (LOD) was for 96.2% (127/132) NALC/NaOH pellets and 94.7% (125/132) for sputum samples. Table 1 shows the RT MTB RIF/INH data by microscopy result.
A total of 122 subjects had RT MTB RIF/INH results for both NALC/NaOH pellets and sputum. One hundred percent (122/122) of these paired RT MTB RIF/INH results were in agreement. The 122 RT MTB RIF/INH results were compared against those of the gold standard, DST. To ensure that the same data set was analyzed, the same 122 subjects were analyzed for Xpert and Hain versus DST.
The comparative data for RIF resistance detection are shown in Table 2 .
The probe detection patterns were available for both RT MTB RIF/INH and Xpert (but not for Hain RIF or INH responses), thus allowing a comparison of these patterns. The RT MTB RIF/INH uses eight probes to detect RIF resistance, while Xpert uses five probes (A-E).
7,13 28 samples had RT 
Discussion
This study assessed the performance of RT MTB RIF/INH when used to test paired sputum and NALC/NAOH pellets of sputum collected from Bangladeshi TB subjects. The direct testing mode was used in contrast to the reflex mode used in other evaluations of RT MTB RIF/INH. [10] [11] [12] The level of invalid RT MTB RIF/INH results was 0% in both sputum and NALC/NaOH specimens. This is consistent with the other evaluations of RT MTB RIF/INH where the percent of invalid RT MTB RIF/INH results was negligible. [10] [11] [12] This suggests that the RT MTB RIF/INH sample preparation protocol was well optimized to process respiratory specimens (sputum, NALC/NaOH pellets of sputum). This is the first evaluation where paired sputum and NALC/NaOH pellets prepared from sputum were evaluated. One hundred percent of the paired results were in agreement, suggesting that the RT MTB RIF/INH assay has good reproducibility across sample types. As was seen in the other evaluations, some samples tested using RT MTB RIF/INH had results of "Below LOD." [10] [11] [12] In another study, the LOD of RT MTB RIF/INH was determined to be 60 cfu/mL in sputum when used to test a quantitated culture of MTB H37Rv diluted in 
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Kostera et al pooled sputum. 7 In this study, "Below LOD" results were more frequent in smear negative-specimens (15%) than in specimens with smear-positive results (1.8%-3.6%). There was not a large difference in the frequency of "Below LOD" results when paired sputum (5.3%) and NALC/NaOH (3.8%) samples were tested suggesting that the RT MTB RIF/INH has similar sensitivity in these two sample types. Similar rates of "Below LOD" RT MTB RIF/INH results were observed in two other studies. 10, 11 In this paper, we report on the sensitivity and specificity vs phenotypic DST of RT Per WHO guidelines, TB subjects infected with RIFand INH-sensitive disease should be treated with front-line therapy, while those infected with RIF-and INH-resistant, or RIF-resistant and INH-sensitive TB, should be treated with second-line therapy. 1, 14 Rapid NAAT that detect RIF resistance are very useful for such patients. However, this type of NAAT would not have detected the 2.5% of patients in this population with RIF-sensitive but INH-resistant disease. Rapid detection of RIF-sensitive, INH-resistant patients is useful because efficacy of front-line therapy is reduced in such patients. 15 NAAT that detect both RIF and INH resistance, such as RT MTB RIF/INH, therefore may complement phenotypic DST for the detection of resistance that impacts front-line therapy. [2] [3] [4] [5] [6] Given that DST is the accurate but slow gold standard for detection of drug-resistant MTB, more rapid NAAT are being widely implemented. The level of implementation of NAAT varies by country. The RT MTB RIF/INH assay is an alternative NAAT to the two WHO-endorsed NAAT. It may prove useful in certain testing situations, in particular those that benefit from centralized, automated batch testing.
